⚠ Disclaimer: This report is generated using AI tools and is for informational purposes only. It does not constitute investment advice. Please consult a registered financial advisor before making any investment decisions.
DIVISLAB - Fundamental Analysis: Financial Health & Valuation
Back to ListFundamental Rating: 3.8
| Stock Code | DIVISLAB | Market Cap | 1,62,973 Cr. | Current Price | 6,137 ₹ | High / Low | 7,078 ₹ |
| Stock P/E | 63.3 | Book Value | 578 ₹ | Dividend Yield | 0.49 % | ROCE | 20.6 % |
| ROE | 15.6 % | Face Value | 2.00 ₹ | DMA 50 | 6,264 ₹ | DMA 200 | 6,235 ₹ |
| Chg in FII Hold | 0.69 % | Chg in DII Hold | -0.50 % | PAT Qtr | 653 Cr. | PAT Prev Qtr | 696 Cr. |
| RSI | 43.3 | MACD | -28.2 | Volume | 1,81,338 | Avg Vol 1Wk | 2,03,743 |
| Low price | 4,942 ₹ | High price | 7,078 ₹ | PEG Ratio | -6.88 | Debt to equity | 0.01 |
| 52w Index | 56.0 % | Qtr Profit Var | 9.88 % | EPS | 94.8 ₹ | Industry PE | 27.6 |
📊 Core Financials
- Revenue Growth: PAT declined slightly (₹653 Cr vs ₹696 Cr), showing mild earnings pressure
- Profit Margins: EPS ₹94.8, strong profitability
- Debt Ratio: Very low leverage (Debt-to-Equity 0.01)
- Cash Flows: Stable, supported by consistent pharma demand
- Return Metrics: ROCE 20.6%, ROE 15.6% — healthy efficiency
💹 Valuation Indicators
- P/E Ratio: 63.3 (well above industry PE of 27.6, overvalued)
- P/B Ratio: ~10.6 (premium valuation)
- PEG Ratio: -6.88 (negative, weak growth outlook)
- Intrinsic Value: Current price ₹6,137 is near support (₹4,942), but valuation remains stretched
🏢 Business Model & Competitive Advantage
- Global pharmaceutical manufacturer specializing in APIs and intermediates
- Strong export presence and diversified product portfolio
- Debt-free balance sheet enhances resilience
- Dividend yield of 0.49% provides modest shareholder return
📈 Entry Zone & Long-Term Guidance
- Entry Zone: ₹5,800–₹6,100 range (near support levels)
- Long-Term Holding: Attractive due to strong efficiency and global demand
- Risk: Premium valuation and negative PEG ratio may limit short-term upside
✅ Positive
- Debt-free company ensures strong financial stability
- Strong ROCE and ROE metrics compared to peers
- FII holdings increased (+0.69%), showing foreign investor confidence
⚠️ Limitation
- P/E ratio significantly higher than industry average
- Negative PEG ratio indicates poor growth prospects
- Quarterly PAT declined from ₹696 Cr to ₹653 Cr
📰 Company Negative News
- DII holdings decreased (-0.50%), showing reduced domestic investor confidence
- Stock trading below DMA 50 & DMA 200, showing weak momentum
🌟 Company Positive News
- FII holdings increased (+0.69%), showing foreign investor support
- Strong EPS of ₹94.8 supports valuation
🏦 Industry
- Pharmaceutical sector with strong global demand
- Industry PE at 27.6, DIVISLAB trades far above this, showing premium valuation
- Sector growth supported by healthcare demand and exports
🔎 Conclusion
- DIVISLAB is financially strong with excellent ROE/ROCE and debt-free operations
- Valuation is expensive compared to industry peers
- Entry near ₹5,800–₹6,100 is favorable for long-term investors
- Best suited for portfolios seeking pharma exposure with moderate risk tolerance